Video Experimental Relacionado

Updated: Sep 10, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Las vesículas extracelulares liberadas por el factor VIIa atenuan la artropatía hemofílica inducida por la hemorragia

Padmavathi Kavadipula¹, Shiva Keshava², Kaushik Das³

¹The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.

|August 20, 2025

Resumen

Las vesículas extracelulares (VE) liberadas por el factor VIIa muestran potencial terapéutico para la artropatía hemofílica (AH). Estos eEV, que contienen microRNA10a, reducen la inflamación y el daño articular sin afectar la hemostasis.

Área de la Ciencia:

Investigación biomédica
Hematología
Biología molecular

Sus antecedentes:

La artropatía hemofílica (HA) se deriva de la inflamación crónica de las articulaciones debido a la hemorragia repetida.
El tratamiento con el factor VIIa (FVIIa) libera vesículas extracelulares endoteliales (VEE) con propiedades antiinflamatorias.

Objetivo del estudio:

Investigar el efecto terapéutico de los eEV liberados por FVIIa en el HA.
Aclarar el mecanismo subyacente a los efectos protectores de los vehículos eléctricos liberados por FVIIa.

Principales métodos:

Los ratones con hemofilia (F8-/-) sufrieron sangrado articular inducido y fueron tratados con solución salina, eEV de control o eEV liberados por FVIIa.
Las articulaciones de la rodilla fueron analizadas histológicamente e inmunohistoquímicamente para detectar signos de HA.
El papel de microRNA10a (miR10a) fue evaluado utilizando inhibidores e imitadores cargados en eEVs.

Principales resultados:

Los eEV liberados por FVIIa redujeron significativamente la hiperplasia sinovial, la infiltración de los macrófagos, la neoangiogénesis, la degeneración del cartílago y la apoptosis de los condrocitos en ratones HA.
La inhibición de miR10a en los eEV liberados por FVIIa suprimió su efecto protector.
La carga de miR10a en los eEV de control confirió protección y redujo la producción de IL-6 en la sinovia.

Conclusiones:

Los eEV liberados por FVIIa ejercen efectos protectores contra la artropatía hemofílica.
El beneficio terapéutico está mediado, al menos en parte, por el microARN10a.
Los EVs que contienen miR10a representan una estrategia terapéutica prometedora para suprimir la inflamación sinovial en el HA.

Más Videos Relacionados

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Videos de Conceptos Relacionados

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...